idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
idw - Informationsdienst
Wissenschaft
In collaboration with an international team of scientists, Prof. Eleftheria Zeggini from Helmholtz Munich and the Technical University of Munich (TUM) has conducted a comprehensive study with data from millions of individuals. Their research unveiled over 600 disease-associated genetic loci and generated risk scores for diabetes complications.
The genetic information in our cells harbors secrets about the risks, progression, and complications of many diseases. With hundreds of millions of patients worldwide, identifying and understanding genetic risk for type 2 diabetes is of particular interest.
In collaboration with an international team of scientists, Prof. Eleftheria Zeggini from Helmholtz Munich and the Technical University of Munich (TUM) has conducted a comprehensive study with data from millions of individuals. Their research unveiled over 600 disease-associated genetic loci and generated risk scores for diabetes complications.
The insights from the largest type 2 diabetes genome-wide association study to date are now published in Nature.
The prevalence of diabetes continues to increase significantly. According to the WHO, over 400 million people worldwide are living with type 2 diabetes (T2D), a disease with various symptoms and causes. Even though effective treatment options are becoming available, the option for precision medicine is still limited. For many patients, treatment strategies still rely on trial and error. Importantly, T2D can lead to numerous secondary health issues, and there is a critical need for a deeper comprehension of the disease mechanisms to predict the risk of T2D complications and intervene early.
Largest Study on Genetic Risk for Diabetes Now Published
Collaboration among scientists is essential for evaluating vast patient data and achieving a comprehensive understanding of genomic risk variants. Helmholtz Munich scientists are part of the newly formed Type 2 Diabetes Global Genomics Initiative (T2D-GGI). The first outcome of the initiative is the largest genome-wide association study (GWAS) to date. GWAS is a scientific method used to find genetic variation associated with a disease.
The new study encompasses over 2.5 million individuals (428,452 with T2D). Eleftheria Zeggini, senior corresponding author of the study, remarks: “We have carried out the largest genome-wide association study for type 2 diabetes as a collaborative achievement of hundreds of researchers from across the globe. We have found novel genetic risk loci for the disease and have constructed genetic risk scores that are associated with harmful complications.”
The authors used cutting-edge computational approaches to integrate data across multiple -omics modalities. They identified eight distinct mechanistic clusters of genetic variants associated with T2D and discovered associations between individual clusters and diabetes complications.
“Our work leads to an improved understanding of disease-causing biological mechanisms. Better knowledge of progression risk for T2D complications can help put in place early interventions to delay or even prevent these debilitating medical conditions,” says Eleftheria Zeggini.
About Helmholtz Munich
Helmholtz Munich is a leading biomedical research center. Its mission is to develop breakthrough solutions for better health in a rapidly changing world. Interdisciplinary research teams focus on environmentally triggered diseases, especially the therapy and prevention of diabetes, obesity, allergies, and chronic lung diseases. With the power of artificial intelligence and bioengineering, researchers accelerate the translation to patients. Helmholtz Munich has more than 2,500 employees and is headquartered in Munich/Neuherberg. It is a member of the Helmholtz Association, with more than 43,000 employees and 18 research centers the largest scientific organization in Germany. More about Helmholtz Munich (Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH): www.helmholtz-munich.de/en
Prof. Dr. Eleftheria Zeggini, Director at the Institute of Translational Genomics at Helmholtz Munich, Liesel Beckman Distinguished Professor of Translational Genomics at TUM
eleftheria.zeggini@helmholtz-munich.de
Suzuki et al. (2024): Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. Nature. DOI: 10.1038/s41586-024-07019-6
https://www.nature.com/articles/s41586-024-07019-6
Merkmale dieser Pressemitteilung:
Journalisten, Wissenschaftler, jedermann
Biologie, Medizin
überregional
Forschungsergebnisse
Englisch
Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.
Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).
Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.
Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).
Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).
